好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Pomgulated Methionil (LY2140023) in Schizophrenia Patients: A Systematic Review and Meta-analysis
Aging, Dementia, and Behavioral Neurology
P6 - Poster Session 6 (5:00 PM-6:00 PM)
13-001
We aim to provide an overview of pomogulated methionil  (LY2140023 monohydrate) and evaluate its efficacy in comparison to both placebo and atypical antipsychotics by performing a systematic review and meta-analysis

Pomaglumetad methionil (LY2140023 monohydrate) is a potent and selective agonist for metabotropic glutamate receptors (mGluR2/3). Unlike traditional antipsychotics, it does not directly interact with dopamine or serotonin (5-HT2A) receptors, potentially offering a novel mechanism of action with a different side-effect profile.

A comprehensive literature search was conducted to identify relevant studies. The included studies investigated the effect of Promogulated methionil. The quality of studies was assessed using the Cochrane Risk of Bias 2 (ROB-2) Statistical analysis was conducted using Review Manager (revman) with outcomes expressed as Mean differences (MD) with 95% confidence intervals (CI).
The systematic review included 4 randomized clinical trials (RCTs). The analysis revealed that pomaglumetad methionil (LY2140023) didn’t have a statistically significant effect on PANNS compared to placebo (p-value = 0.31) and it was less effective in decreasing PANSS score in comparison to atypical antipsychotics (p-value < 0.00001). However, the drug showed a significant effect on weight gain (p-value < 0.00001) and prolactin (p < 0.0001) in comparison to atypical antipsychotics.
In conclusion, this systematic review and meta-analysis provide evidence that pomaglumetad methionil (LY2140023) does not demonstrate consistent efficacy in the treatment of schizophrenia. Although the compound is associated with a more favorable profile regarding weight gain and prolactin elevation, these advantages do not compensate for its lack of therapeutic efficacy
Authors/Disclosures
Hossam Younis, MD, MBBS
PRESENTER 		Dr. Younis has nothing to disclose.
Hala AbouShawareb, MD Dr. AbouShawareb has nothing to disclose.
Omar F. Abbas Omar F. Abbas has nothing to disclose.
Hend A. Ghabour, Sr., MD Dr. Ghabour has nothing to disclose.
Ali N. Shelbaya, MD Dr. Shelbaya has nothing to disclose.
Rahma I. Abdelsalam, MBBS Dr. Abdelsalam has nothing to disclose.
Mostafa M. Meshref, MD (Al-Azhar University, Cairo) Dr. Meshref has nothing to disclose.